Why Moderna Trounced the Market on Thursday
Hardly for the first time since the rise of the COVID delta variant, star coronavirus stock Moderna (NASDAQ: MRNA) well outpaced the S&P 500 index on Thursday. On positive if not astounding news, the biotech's stock finished with a gain of just under 2% on the day, against the index's marginal improvement.
The main stock-moving news item for Moderna over the past day seems to be its latest submission to the Food and Drug Administration (FDA).
Specifically, the biotech filed the initial data on booster doses of its mRNA-1273 coronavirus vaccine after market hours on Wednesday. In doing so, it added that it aims to repeat the feat with other regulators around the world in a matter of days. This list includes the European Medicines Agency (EMA), which covers the sprawling, 27-country European Union.
Source Fool.com
